众华会计师事务所（特殊普通合伙） 对《关于对上海润达医疗科技股份有限公司 2024 年度报告的 事后审核问询函》中相关问题的专项说明 众华会计师事务所（特殊普通合伙） 对《关于对上海润达医疗科技股份有限公司 2024 年度报告的事 后审核问询函》中相关问题的专项说明 众会字（2025）第 09689 号 上海证券交易所： 众华会计师事务所（特殊普通合伙）（以下简称"我们"）接受委托对上海 润达医疗科技股份有限公司（以下简称"公司"）2024 年财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并 及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注进行审 计，并于 2025 年 4 月 24 日出具了众会字(2025)第 04148 号的无保留意见审计报 告。 我们于近日收到了公司转来的贵所出具的《关于对上海润达医疗科技股份 有限公司 2024 年度报告的事后审核问询函》（上证公函【2025】0796 号）（以下 简称《问询函》）。我们根据问询函的要求对问询函中与财务会计相关的问题进 行了核查，回复如下： 一、关于经营业绩。年报显示，报告期内 ...

Investment Rating - The investment rating for the computer industry is "Positive" (maintained) [1] Core Viewpoints - The stablecoin and AI industries are continuously catalyzing growth, with major players actively positioning themselves and policies enhancing the landscape, marking a "singularity" moment for stablecoins [5][12] - AI computing power remains robust, with the upcoming release of GPT-5 expected to further enhance reasoning capabilities and stimulate AI application growth [6][13] Summary by Sections Weekly Perspective - The Shanghai Composite Index rose by 1.54% while the computer index fell by 1.28% during the week of June 30 to July 4, 2025 [4][11] Industry Trends - The People's Bank of China is expanding the application scenarios of the digital RMB in foreign trade, while Ant Group and JD.com are advancing into the stablecoin space, aiming to reduce cross-border payment costs by 90% and improve efficiency to within 10 seconds [5][12] - Oracle signed a significant cloud service agreement expected to generate over $30 billion annually starting from the 2028 fiscal year, indicating strong demand for AI computing power [6][13] Investment Recommendations - For stablecoins and RWA, recommended companies include Langxin Group and Zhuoyi Information, with beneficiaries such as Zhongke Software and New Morning Technology [14] - For AI applications, recommended companies include Kingsoft Office and iFlytek, with beneficiaries like Meitu and Hanbang High-Tech [7][14] - In the computing power sector, recommended companies include Zhongke Shuguang and Chunzhi Technology, with beneficiaries such as Cambrian and Unisplendour [7][14]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-034 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于实施 2024 年度权益分派时转股连续停牌的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2024 年度权益分派,本公司的相关证券停复牌情况如下： 本次权益分派方案实施后，公司将根据《上海润达医疗科技股份有限公司公 开发行可转换公司债募集说明书》的发行条款及相关规定，对"润达转债"当期 转股价格进行调整。 二、本次权益分派方案实施时转股连续停牌的安排 1、公司将于2025年7月11日在《中国证券报》、《上海证券报》、《证券日 报》、《证券时报》及上海证券交易所网站（www.sse.com.cn）上发布权益分派 实施公告和可转债转股价格调整公告。 2、自 2025 年 7 月 10 日至权益分派股权登记日期间，"润达转债"将停止转 股，股权登记日后 ...

| | | 上海润达医疗科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司本次发行的"润达转债"的转股期为 2020 年 12 月 23 日至 2026 年 6 月 16 日。 在 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，共有人民币 180,000 元的"润 达转债"已转换成公司股份，转股数量为 13,839 股。截至 2025 年 6 月 30 日， 累计人民币 315,655,000 元的"润达转债"转换成公司股份，占可转债发行总量 57.3918%，累计转股数量为 24,130,185 股，占可转债转股前公司已发行股份总额 的 4.1637%。 截至 2025 年 6 月 30 日，尚未转股的"润达转债"金额为人民币 234,345,000 元，占可转债发行总量的 42.6082%。 三、股本变动情况 单位：股 一、可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限 ...

上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-033 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 担保对象及基本情况 | 资产负债率为 | | 70%以上的全资及控股子公司 | | | | | --- | --- | --- | --- | --- | --- | | 担 保 | 对 | 被担保人名称 | | 杭州润达医疗管理有限公司 | | | | | 本次担保金额 | 16,592 | 万元 | | | 象一 | | 实际为其提供的担保余额 | 166,607.44 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 ...

Investment Rating - The report maintains a "Recommended" investment rating for the computer industry [2][9]. Core Viewpoints - Ant Group has launched an AI health application, AQ, aimed at simplifying medical processes and enhancing health management efficiency, connecting over 5,000 hospitals and nearly one million doctors [5][9]. - The AI healthcare sector is rapidly developing, with major players accelerating their investments, addressing traditional healthcare challenges, and promoting the informatization and accessibility of medical services [9]. Summary by Sections Recent Developments - On June 26, 2025, Ant Group officially launched the AI health application AQ, which integrates various health management functions and provides 24/7 medical services [3][5]. Key Features of AQ - AQ includes intelligent consultation, multi-modal interaction, online-to-offline consultation pathways, and collaboration with health device manufacturers to create a personalized health management ecosystem [5][6]. Market Trends - The AI healthcare market in China is expanding, with a projected compound annual growth rate (CAGR) of 11.7% from 2023 to 2028, reaching a total market size of 35.75 billion yuan by 2028 [5][9]. - Companies like Huawei and Tencent are also making significant strides in AI healthcare solutions, indicating a competitive landscape [5][9]. Investment Recommendations - The report suggests focusing on companies with strong technological reserves and rich medical data in the fields of chronic disease management and medical informatization, including Weining Health, Meinian Health, Chuangye Huikang, Dongsoft Group, Rundar Medical, Keda Xunfei, and Jiahe Meikang [9].

Investment Rating - The report assigns an "Outperform" rating for the industry [1][5]. Core Insights - The report highlights the continuous catalysis of AI in healthcare, emphasizing the positive outlook for domestic AI healthcare development [2]. - It notes the increasing aging population in China, with 310 million people aged 60 and above by 2024, representing 22% of the total population, which necessitates the efficiency improvements offered by AI healthcare tools [3]. - The report discusses various AI healthcare applications, including multi-modal imaging diagnostics, integration with genomics for precision medicine, advancements in surgical robotics, and the rise of remote healthcare and health management [3]. Summary by Sections AI Healthcare Developments - A series of strategic partnerships and product launches in AI healthcare were reported, including a collaboration between Aier Eye Hospital and Huawei Cloud, and the IPO filing of Weimai, which focuses on AI-enabled medical services [2]. - Ant Group launched a new AI health application, "AQ," connecting over 5,000 hospitals and nearly a million doctors [2]. Market Trends - The report identifies key trends in AI healthcare, such as the shift from B2B to B2C applications, the evolution of AI in medical imaging, and the integration of AI with wearable devices for continuous health monitoring [3]. - The deployment of large AI models in over a hundred top-tier hospitals signifies the comprehensive integration of AI into healthcare settings [3]. Related Companies - The report mentions several companies related to AI healthcare, including Madi Technology, Meinian Health, Xiangyu Medical, Rundat Medical, Weining Health, and Jiahe Meikang, although it notes that most of these companies have not yet been covered by research reports [4].

Group 1 - The core viewpoint of the articles highlights a transformative shift in the healthcare industry driven by AI, with companies like Tempus AI and Ant Group leading the charge in utilizing data to enhance medical services and patient care [1][4][6] - Tempus AI has built a comprehensive business model that spans drug development, clinical decision-making, and patient management, leveraging a vast database of 250 million patient genetic profiles and clinical data [1][4] - Ant Group's AI health assistant AQ aims to address the healthcare needs of 1.4 billion people in China, marking a significant advancement in the integration of AI into the healthcare system [1][2] Group 2 - The articles emphasize that AI is a pathway to achieving universal healthcare, addressing the deep-seated issues of resource scarcity and uneven distribution in China's medical system [2][4] - Ant Group's approach involves a "technology-scenario-clinical" model that connects 3,600 hospitals and aggregates resources from one million doctors, focusing on balancing data security and clinical effectiveness [5][6] - The global AI healthcare market is projected to grow at a compound annual growth rate of 43%, reaching a size of $491 billion, indicating a strong commercial potential for AI-driven healthcare solutions [5][6] Group 3 - The core contradiction in the AI healthcare industry is shifting from competition over large models and computing power to the deep exploration of data value [6][8] - Companies are now focusing on leveraging high-quality, multi-modal data assets to create competitive advantages, moving away from merely building technical barriers [6][8] - The application layer of AI in healthcare is evolving towards preventive services, online consultations, and rehabilitation management, creating a comprehensive health management ecosystem [6][8]

Group 1 - The company's主体信用等级 is maintained at "AA" with a stable rating outlook [1][2] - The credit ratings for the issued "润达转债" and "23 润达医疗 MTN001" are also maintained at "AA" [1][2] - The credit rating agency, 新世纪评估, conducted a comprehensive analysis of the company's industry and operational status before confirming the ratings [2]

Core Viewpoint - The company, Shanghai RunDa Medical Technology Co., Ltd., is positioned well in the in-vitro diagnostic (IVD) market, benefiting from strong demand driven by economic growth, aging population, and upgrading medical consumption structure [1][3][6]. Company Overview - RunDa Medical focuses on the IVD sector, establishing a nationwide business layout and accumulating a significant customer and supplier base [1][3]. - The company has introduced state-owned capital as a controlling shareholder, enhancing its financial channels and collaboration with public healthcare institutions [3][6]. Market Environment - The IVD market is characterized by strong demand due to factors such as economic growth, an aging population, and increased healthcare spending [6][8]. - The industry faces challenges from regulatory changes and intense competition, which may impact revenue and profitability [3][6][8]. Financial Performance - The company's revenue has shown a decline, with total revenue for 2024 at 83.06 billion, down from 91.40 billion in 2023, reflecting a 9.13% decrease [8][9]. - The gross profit margin has also decreased, with a comprehensive gross margin of 25.37% in 2024 compared to 26.58% in 2023 [8][9]. Business Operations - RunDa Medical operates two main business segments: commercial comprehensive services and industrial services, with the commercial segment contributing over 90% of total revenue [10][12]. - The company has expanded its service offerings to include AI medical solutions, collaborating with major hospitals and healthcare institutions [9][10]. Competitive Position - The company has established a robust supply chain with over 1,200 suppliers and nearly 19,000 product varieties, ensuring comprehensive coverage of the IVD market [19][20]. - RunDa Medical's focus on R&D in IVD products and digital solutions positions it competitively within the industry [20]. Future Outlook - The company anticipates stable credit quality in the coming months, although potential downgrades may occur due to significant performance deterioration or changes in major stakeholders [3][4]. - Continued investment in AI and digital health solutions is expected to enhance market competitiveness and operational efficiency [9][10].